Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. PGDx is developing an innovative portfolio of regulated tissue-based and non-invasive liquid biopsy genomic products for laboratories worldwide. PGDx offers elio Tissue Complete, the first and only clinical next-generation sequencing diagnostic kit for comprehensive tumor profiling that is FDA-cleared for use in labs across the country. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.
PGDx